6th Meridian Drug Discovery 2023

Strategy You Need,

Results You Desire

May 18th – 19th 2023

New York, USA

Meridian Drug Discovery is a bi-annual event series hosted by Continuum Globe Ltd. A venue for exchanging scientific knowledge and a business incubator for vendor and sponsor engagements. Networking, knowledge exchange, and partner outreach are all made more accessible by MDD.

Our team collaborates with premier research institutes, private pharma-biotechs, and contract research firms to publish the most recent scientific and technological advances.

Meridian Drug Discovery assists businesses in enhancing their overall approach for hit discovery, validation, and research, as well as their study design. For the 6th Meridian Drug Discovery, we have centralized our scientific approach to Artificial Intelligence, AI-driven drug design, drug safety, enhanced lead selection, and more.

EVENT WILL START IN
  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Add to My Calendar 2023-05-18 12:00:00 2023-05-19 18:00:00 United States/New York 6th Meridian Drug Discovery Meridian Drug Discovery is a bi-annual event series hosted by Continuum Globe Ltd. A venue for exchanging scientific knowledge and a business incubator for vendor and sponsor engagements. Networking, knowledge exchange, and partner outreach are all made more accessible by MDD. New York, USA Continuum Globe Ltd info@continuumglobe.com

OUR SPEAKERS

Andy Lee

Vinod Das

Co-founder & COO

Biography

Once you realize biological age is measurable and adjustable, it is impossible to think about anything else. The impact and upside from longevity interventions will define our generation – are you ready to join the fight?

Terry Barnhart

Vinod Das

Organizational Development

Biography

Organizational design, effectiveness and transformation executive in the biopharmaceutical industry. I have led the redesign of global and country-based R&D organizations for 3 multinational companies and delivered nearly $ 1 billion in operational value through R&D acceleration.

Biography

Advancing drug discovery with innovation and technology.

Winner of CSO’s award for innovation.

Co-led medicinal chemistry

Co-led the research informatics guiding team

Extensive experience in identifying and evaluating various companies and technologies to drive innovation in discovery.

Built, led, and managed high throughput screening, protein crystallography, SPR, compound management, NMR spectroscopy, bioinformatics, cheminformatics, molecular modeling, and high throughput purification.

Build and leads high-functioning teams.

Works across infection, pain, oncology, inflammation, metabolic disease, and Alzheimer’s.

Led external science relationships with Evotec, Biofocus, Forma, Heptares, Beactica, and multiple postdoctoral fellows.

Marcin von Grotthuss

Marcin von Grotthuss

Principal Scientist

Biography

Senior Computational Scientist with 18 years of experience in developing sophisticated, analytical, bioinformatics algorithms, pipelines, and portals as well as applying them to understand complex biological data.

Credo: the properly conducted analysis of combined clinical, molecular and genomic data can be easily translated into clinical applications to increase the success rate of drug developments and to provide personalized medicine solutions to patients.

Arnold Lippa

Arnold S. Lippa

Chief Scientific Officer, Executive Chairman of Board of Directors

Biography

Dr. Lippa has served as Executive Chairman since March, 2013 and Chief Scientific Officer since August, 2015. From March, 2013 until August, 2015 and from September, 2018 until May, 2020, he also served as President and Chief Executive Officer, respectively.

He is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a firm of which Mr. Margolis is the president and founder and which has served as a placement agent with respect to certain of the Company’s prior financings. Aurora was SEC registered and a FINRA member firm until voluntarily withdrawing effective July 2021 and has been inactive in the securities and investment banking industry since April 2021.

Dr. Lippa and Mr. Margolis founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Both entities are currently inactive. Dr. Lippa is a member of the Board of Directors of ContraVir Pharmaceuticals, Inc. since December 2015, where he is a member of the audit committee and the compensation committee. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005 and which he took public in 2002.

Vinod Das

Vinod Das

Associate Director

Biography

Experienced techno-functional leader with demonstrated history of empirical contributions to Consumer Health, Healthcare, Pharmaceuticals, Research Laboratories, Automotive & Aerospace Domains

Highly organized, self-motivated, innovative and science-driven strategist with working experiences as Director, Delivery Manager, Solutions Architect, Lab Informatics (LIMS/ELN), Development & Applications Maintenance for R&D systems.

Well-versed in working with diverse cultures providing effective & tangible outcomes through smart directional leadership. Always embracing & measuring team goals for OKR’s [Objectives and Key Results]

Margaret K Offermann

Margaret K Offermann

CEO

Biography

Margaret K. Offermann, MD, PhD is a medical oncologist, tumor biologist, educator and executive with professional experience in academic, philanthropic and private sectors. She is the CEO of OncoSpherix, a preclinical stage cancer drug development company that is advancing a first-in-class family of small molecules that block the ability of cancer cells to adapt and spread from regions of low oxygen that results from growing faster than the blood supply.

Dr. Offermann previously served as Managing Partner of the Salutramed Group (a boutique C-level consulting group), Deputy National Vice President for Research at the American Cancer Society and Professor of Hematology and Oncology at Emory University, where she served as co-director of the MD, PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute.

She has served in executive roles with numerous non-profit organizations, including serving as President of the Federation of American Societies for Experimental Biology (FASEB), a federation of 30 non-profit research societies with over 130,000 members that advances biological science through collaborative advocacy for research policies that promote scientific progress and education.

John Lu

John Lu

President & CEO

Biography

John Lu is currently the President and CEO of HebeCell Corporation. Established in April of 2016, HebeCell focuses on the fields of Immunotherapy and Regenerative Medicine. Our mission is to develop and commercialize human iPSC-based cell therapeutics for multiple human diseases.

HebeCell has developed a platform technology using a scalable 3-D bioreactor system for the expansion and differentiation of human iPSCs towards immune and other lineages. Based on this 3D platform, HebeCell currently has two ongoing programs: 1) Immunotherapy Program: human iPSC-derived off-the-shelf CAR-NK Cells for the treatment of multiple tumours including blood and solid tumours, as well as autoimmune and infectious diseases; 2) Ocular Program: human iPSC-derived photoreceptor progenitors for the treatment of macular degeneration including Retinitis Pigmentosa, Stargardt’s Disease and Age-related Macular Degeneration (AMD).

Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics from 2005 to 2016, which was acquired by Astellas in 2016, the 2nd largest pharmaceutical company in Japan. During his tenure at ACT/Ocata, John developed the hemangioblast, red blood cell, MK/platelet and MSC programs, as well as photoreceptor and retinal ganglion cell programs.

James Leamon

James Leamon

Director, Biologics Device Development

Biography

Medical device and drug-device combination product development leader, engineering director, manufacturing manager and experienced in working across functions and business groups in varying organizations. Have successfully brought new and effective products to market throughout the world, and developed and implemented new engineering, quality control and manufacturing processes. Lead Product Development, and Engineering teams.

Highly experienced and proficient in engineering and project management activities: strategic planning, design engineering, manufacturing engineering, design control, prioritization, contract engineering management, resource allocation, new product and process development.

Specialties: Product development, project leadership and project management, combination product medical devices, laboratory process automation, regulatory standards and process, cross-functional communication, engineering management, product development

Rangaprasad Sarangarajan

Rangaprasad Sarangarajan

Chief Scientific Officer

Biography

Over a decade of experience in identifying unique differentiated opportunities, and building/implementing plans and teams to create value for commercial success. Significant expertise in leading cross-functional teams in the deployment of AI analytics/machine learning integration to domain-specific RWD/RWE environments enabling rapid, synchronous translation of early discovery R&D, target tractability, drug discovery & pharmaceutical development. Reputation for creativity, innovation, critical thinking and ability to deliver with strong scientific expertise in translational sciences.

Neelima Khairatkar-Joshi

Neelima Khairatkar-Joshi

Founder and President

Biography

Current Position:

President and Founder, Promethean Drug Ideas, Proprietary Scientific Consultation Firm (http://www.prometheandrugideas.com). (2020 till to date) Esteemed Clients: NYU Lagone Health, New York, USA, Sravathi AI Technology Pvt Ltd, Bangalore, India, AURO University, Ahmedabad, India & Other Undisclosed

Background & Accomplishments:

    Over 30 years of experience in New Drug Discovery Research from 2 MNCs, last a decade as SVP & NCE research head.

  • Glenmark Pharmaceuticals: Sr. Vice President and Head, NCE Research. (Y2000 to 2020)
  • Hoechst Marion Roussel / (Sanofi Aventis now) Scientist, Molecular Biology, (1993-2000)

  • Delivered eight NCEs as IND candidates for first-in-human studies, six being first-in-class molecules.
  • A significant contribution towards proprietary NCE out-licensing deals that brought cash inflow of 180 Mio $ for the organization
  • Inventor on 92 published world patents (PCTs), 50 international presentations/ 30 peer reviewed publications / book chapters.
  • Ph.D. in Molecular Biology, BARC, INIDA (1991)

RELEVENT JOB FUNCTIONS

The audience comprise of Senior Executives & Departmental Heads from following departments.

Scientists
Scientists
Discovery Alliance
Discovery Alliance
Discovery Chemistry
Discovery Chemistry
Pharmacokinetics
Pharmacokinetics
Research & Development
Research & Development
Drug Design
Drug Design
Discovery Portfolio
Discovery Portfolio
Molecular Biology
Molecular Biology
Pharmacology
Pharmacology
Translational Medicine
Translational Medicine
Target Discovery
Target Discovery
Toxicology
Toxicology
DMPK
DMPK
Genomics
Genomics
Compound Screening
Compound Screening
Discovery Strategy
Discovery Strategy
Compound Profiling
Compound Profiling
Pharmacodynamics
Pharmacodynamics
Medicinal Chemistry
Medicinal Chemistry
Preclinical
Preclinical & More

EVENT FEATURES

Quick Glace of some of the favorite Features of MDD.

THE SCHEDULE

Registration

8:15 - 8:45 AM

Opening Remarks

8:45 - 9:00 AM

Presentation 1

Strategies for building a sustainable drug discovery infrastructure

9:00 - 9:25 AM

Presentation 2

AI-enhanced Drug Design & Development: towards a Computational Precision Medicine

9:25 - 9:50 AM

Presentation 3

Reserved for Sponsor Presentation

9:50 - 10:15 AM

Presentation 4

Fragment-Based Drug Design: Advancing Tools and Technologies

10:15 - 10:40 AM

Networking & Coffee

10:40 - 11:10 AM

Presentation 5

Phenotypic Screening in Drug Discovery and High Content Screening Tools

11:10 - 11:35 AM

Panel Discussion 1

Importance of Data Centricity

11:35 - 12:05 PM

Presentation 6

ADCs: a New Class of Drugs Designed as a Targeted Therapy for Cancer

12:05 - 12:30 PM

Presentation 7

Accelerating Drug Discovery Research using High-Content Screening Technology

12:30 - 12:55 PM

Presentation 8

Drug Repurposing (DR): An Emerging Approach in Drug Discovery

12:55 - 01:20 PM

Lunch Break

01:20 - 02:20 PM

Presentation 9

Reserved for Sponsor Presentation

02:20 - 02:45 PM

Presentation 10

Data Visualization to accelerate biological discovery

02:45 - 03:10 PM

Presentation 11

Advanced Bioinformatics Techniques for Biologics Drug Discovery

03:10 - 03:35 PM

Presentation 12

Predicting Drug Toxicity

03:35 - 04:00 PM

Networking & Coffee & Meetings

04:00 - 04:30 PM

Presentation 13

Isotopic Labeling of Metabolites in Drug Discovery applications

04:30 - 04:55 PM

Closing Remarks Day One

04:55 - 05:10 PM

Registration

8:15 - 8:45 AM

Opening Remarks

8:45 - 9:00 AM

Presentation 1

Drug Discovery of New Modalities: Lead Optimization of Peptides and Oligonucleotides

9:00 - 9:25 AM

Presentation 2

The Importance of Collaborative Business Models for Drug Development

9:25 - 9:50 AM

Presentation 3

Reserved for Sponsor Presentation

9:50 - 10:15 AM

Presentation 4

Targets, translation & risk: Conceptual Framework for Drug Discovery Decision Making

10:15 - 10:40 AM

Networking & Coffee Break

10:40 - 11:10 AM

Presentation 5

Harnessing DNA Encoded Libraries

11:10 - 11:35 AM

Panel Discussion 1

Importance of Animal Models & emerging alternatives

11:35 - 12:05 PM

Presentation 6

The Organ-On-A-Chip platform for disease modelling and therapeutic screening

12:05 - 12:30 PM

Presentation 7

RNA optimization is a powerful tool for drug discovery

12:30 - 12:55 PM

Presentation 8

Benefits, limitations, and diversity of AI models in Drug and Target Discovery

12:55 - 01:20 PM

Lunch Break

01:20 - 02:20 PM

Presentation 9

Reserved for Sponsor Presentation

02:20 - 02:45 PM

Presentation 10

Biomarkers in DD and development: from target identification through drug marketing

02:45 - 03:10 PM

Presentation 11

Challenges and opportunities for collaboration and Data sharing

03:10 - 03:35 PM

Presentation 12

Novel approaches for cell & gene therapy – Evolution or Revolution

03:35 - 04:00 PM

Networking & Coffee

04:00 - 04:30 PM

Presentation 13

Increasing efficacy in target identification and validation

04:30 - 04:55 PM

Closing Remarks Day Two

04:55 - 05:10 PM

OUR SPECIALTY

Exclusivity

An exclusive audience from growth stage pharma-biotech companies

Commitment

Maximize ROI for time and investment; we Deliver what we Commit

Professionalism

Experienced executives providing a Premium Experience

Knowledge

Well researched and implementable Knowledge shared by Industry Leaders

PRICING

Choose your favorite pass for the event.

Online Partnership
£500
  • Sponsor Representation
  • Event Material Sharing
  • Sponsor Pack
  • Booklet Profile
  • On-site Marketing
  • Online Marketing

Online Partnership

Poster Presentation
£700
  • Poster Presentation
  • Sponsor Representation
  • Sponsor Pack
  • Booklet Profile
  • On-site Marketing
  • Online Marketing

Poster Presentation

Vendor Attendance
£1400
  • Event Attendance
  • Sponsor Representation
  • Scientific & Networking Sessions
  • Booklet Profile
  • Ad-hoc Meetings
  • On-site & Online Marketing

Vendor Attendance

SERIES SPONSORS

This list represents Previous and Current Sponsors.

SEND US A MESSAGE

If you have any questions about the event, please contact us directly. We will respond for sure.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    LETS GATHER TOGETHER

    JOIN THE CONFERENCE

    back to top

    Call For Abstracts


      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.